Skip to main content
Equibles

SMSPHARMA · SMS Pharmaceuticals Limited

Use SMSPHARMA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SMSPHARMA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
508.05 INR -15.80 (-3.02%) At close · Nov 13
Rebalance outlook locked
Market Cap
47.58B INR
Shares
93.65M
Volume · Nov 13 522.7K Avg daily vol (3M) 823.51K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close508.05 INR Open525.05 INR Day502.05–535.00 INR 52W close271.55–525.50 INR Avg vol 30d617K Last earningsNov 5, 2026 DataJan 2020–Nov 2026

Latest documents

2026
Nov 5
Earnings call
Q2 revenue rises 30%; FY27 targets expected to be exceeded

SMS Pharmaceuticals Limited reported Q2FI27 revenue from operations of 316 crores, up 30% over Q2FI26, and expects to exceed FI27 guidance of 15% revenue growth and a 20% EBITDA margin.

3 source passages
In Q2FI27, revenue from operations stood at 316 crores, a growth of 30% over Q2FI26 and 53% over Q1, driven by strong volumes and improving price realization. For FI27, guidance was revenue growth of 15% with an EBITDA margin of 20%. The pricing in our key APIs is expected to remain stable in the near term, and on the back of a strong first half and the outlook for the rest of the year, we now expect to exceed both. On behalf of SMS Pharmaceuticals Limited, that concludes this conference. Open the document at this passage
All documents

Quarterly results

Revenue Net income Net loss
▲7.4% 1.73B INR 182.61M INR '25 Q3 ▲1% 2.48B INR 1.20B INR '25 Q4 ▲19.2% 1.96B INR 204.91M INR '26 Q1 ▲23.2% 2.42B INR 253.13M INR '26 Q2 ▲21.4% 2.10B INR 234.72M INR '26 Q3 ▼4.1% 2.38B INR 329.96M INR '26 Q4 ▲5.6% 2.07B INR 209.09M INR '27 Q1 LATEST ▲30.4% 3.16B INR 398.53M INR '27 Q2

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its 52-week range
Range low 271.55 INR Now 508.05 INR · 93% Range high 525.50 INR
vs 200-day avg +28% vs 50-day avg +11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

5D 20D 120D MTD YTD
XNSE:SMSPHARMA +1.9% +19.6% +33.2% -0.7% +63.7%

Exchange listing

Market
XNSE
Ticker
SMSPHARMA
ISIN
INE812G01025
Security
Ordinary share
Trading currency
INR

Company

Website
https://smspharma.com/
Investor relations
https://smspharma.com/disclosures-under-regulation-46-of-the-lodr/

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Recent dividends

Ex-dividend dateAmount per share
2026-09-22 0.40 INR
2025-09-22 0.40 INR
2024-09-23 0.40 INR
2023-09-22 0.30 INR
2022-09-22 0.30 INR
2021-09-22 0.30 INR
2020-03-26 0.25 INR
2019-09-19 0.25 INR
2018-09-11 0.25 INR
2017-09-20 0.20 INR
2016-09-22 0.20 INR
2015-09-22 0.20 INR
2014-09-23 0.20 INR
2013-09-23 0.20 INR
2011-09-22 0.15 INR
2010-09-23 0.10 INR

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

  • Earnings call · Q2 2027 2026-11-05 Audio Transcript
    Earnings Call for the Quarter Ended September 30, 2026
  • Earnings call · Q4 2026 2026-05-27 Audio Transcript
    Earnings Call for the Quarter Ended March 31, 2026
  • Conference · May 2026 2026-05-27
    Investor Conference Call to be held on 27.05.2026